:

SNABBIT EYES $400M VALUATION IN FRESH FUNDING ROUND

INDUSTRY DESK1 MIN READ
SAT, APR 25, 2026

■ AI-SUMMARIZED FROM 1 SOURCE BELOW

India's gig economy platform Snabbit is seeking new capital at a $400 million valuation, according to sources familiar with the matter. The funding round comes as the startup demonstrates significant growth momentum.

Snabbit has achieved rapid scaling, surpassing one million jobs completed in March 2024. The milestone underscores expanding demand for its services across India's labor market. The $400 million valuation reflects investor confidence in the platform's business model and growth trajectory. Snabbit connects workers with short-term gig opportunities, positioning itself in a competitive space alongside established players. The fresh capital injection would support expansion efforts and platform enhancements. Investor interest in India's gig economy sector remains strong, driven by rising smartphone penetration and growing workforce participation in flexible work arrangements. Snabbit's fundraising activity signals continued investor appetite for Indian tech platforms targeting emerging market opportunities. The startup joins a cohort of Indian fintechs and service platforms attracting significant venture backing.

■ SOURCES

TechCrunch

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE STARTUPS DESK

Facing AI automation and a competitive job market, Gen Z workers are bypassing traditional corporate entry-level positions to start their own businesses. Recent graduates report struggling to land jobs despite relevant degrees and experience.

4H AGOAI Desk

Thinking Machines Lab has hired more researchers from Meta than any other single employer, according to a LinkedIn analysis. The AI lab now has approximately 140 employees on staff.

12H AGOIndustry Desk

Investor Lachy Groom is set to back Indian house-help startup Pronto in a funding round valuing the company at $200 million, according to sources familiar with the deal.

13H AGOIndustry Desk

Bootstrap Bio and Manhattan Genomics, two companies focused on human embryo editing to prevent genetic diseases, have ceased operations. The closures mark a setback for the controversial field of germline editing.

17H AGOIndustry Desk

■ SUBSCRIBE TO THE DAILY BRIEF

ONE EMAIL, 5 STORIES, 06:00 UTC. UNSUBSCRIBE ANYTIME.